---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-019507"
form_type: "8-K"
ticker: "XFOR"
cik: "0001501697"
company_name: "X4 Pharmaceuticals, Inc"
filed_at: "2025-04-24T23:59:59+00:00"
generated_at: "2026-05-23T06:57:49.109761+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# X4 Pharmaceuticals announces 1-for-30 reverse stock split effective April 28 to regain Nasdaq bid price compliance

## Summary
- Reverse stock split at 1-for-30 ratio effective 12:01 a.m. ET on April 28, 2025; shares trade split-adjusted under XFOR.
- Outstanding shares reduced from ~173.6M to ~5.8M; no fractional shares issued, cash in lieu.
- Split intended to cure Nasdaq minimum bid price deficiency; company received extension to August 11, 2025.
- Proportional adjustments made to equity awards, options, and warrants; CUSIP changes to 98420X202.

## SEC filing metadata
- accession: 0001628280-25-019507
- form_type: 8-K
- ticker: XFOR
- cik: 0001501697
- company_name: X4 Pharmaceuticals, Inc
- filed_at: 2025-04-24T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501697/000162828025019507/0001628280-25-019507-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501697/000162828025019507/xfor-20250424.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-019507
- JSON: https://secwatch.observer/filing/0001628280-25-019507.json
- Plain text: https://secwatch.observer/filing/0001628280-25-019507.txt

## Key facts
- Governance Changes
  X4 Pharmaceuticals, Inc: Filed a certificate of amendment to effect a 1-for-30 reverse stock split of common stock, effective April 28, 2025 (effective 2025-04-28).
  - Change: charter amendment
  - Effective: 2025-04-28
  source text: On April 24, 2025, X4 Pharmaceuticals, Inc. (the “Company”) filed an amendment (the “Certificate of Amendment”) to its Restated Certificate of Incorporation, as amended and/or restated from time to time, to effectuate a reverse stock split of the Company’s issued and outstanding shares of common stock, par value $0.001 per share (the “Common Stock”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501697/000162828025019507/0001628280-25-019507-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.